Drugs by condition
Drugs approved for acute lymphoblastic leukemia
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
19
Still marketed, NDA or BLA
Drug classes
6
Novel drugs
9
New molecular entities and new biologics
In development
9
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for acute lymphoblastic leukemia.
- Oxderys (Doxorubicin Hydrochloride) · Avyxa Holdings Nov 9, 2026
- Imkeldi (Imatinib Mesylate) · Shorla Oncology Nov 22, 2024
- Phyrago (Dasatinib) · Handa Therap OrphanDec 5, 2023
- Jylamvo (Methotrexate) · Shorla Nov 29, 2022
- Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) · Jazz Pharms NovelOrphanJun 30, 2021
All approved drugs for acute lymphoblastic leukemia, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 66 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Asparagine-specific Enzyme (3)
Folate Analog Metabolic Inhibitor (2)
CD22-directed Immunoconjugate (1)
- Besponsa Inotuzumab Ozogamicin · Wyeth Pharms INC · 2017
Nucleoside Metabolic Inhibitor (1)
- Arranon Nelarabine · Sandoz · 2005
Leukocyte Growth Factor (1)
- Leukine Sargramostim · Berlex Labs · 1991
Class not listed in FDA's data (11)
- Blincyto Blinatumomab · Amgen · 2014
- Iclusig Ponatinib Hydrochloride · Takeda Pharms USA · 2012
- Sprycel Dasatinib · Bristol Myers Squibb · 2006
- Purinethol Mercaptopurine · Stason Pharms · 1953
- Oxderys Doxorubicin Hydrochloride · Avyxa Holdings · 2026
- Imkeldi Imatinib Mesylate · Shorla Oncology · 2024
- Phyrago Dasatinib · Handa Therap · 2023
- Purixan Mercaptopurine · Nova Labs LTD · 2014
- Gleevec Imatinib Mesylate · Novartis · 2003
- Doxorubicin Hydrochloride Doxorubicin Hydrochloride · Pfizer · 1987
- Methotrexate Preservative Free Methotrexate Sodium · Hospira · 1959
Drugs in development for acute lymphoblastic leukemia
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- single CNCT19Phase 23 trials
Juventas Cell Therapy Ltd. · Relapsed or Refractory Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- YK012Phase 22 trials
Excyte Biopharma Ltd · Systemic Lupus Erythematosus (SLE), B-cell Acute Lymphoblastic Leukemia
- TGRX-814Phase 21 trial
Shenzhen TargetRx Co., Ltd. · Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia
- UCART22Phase 21 trial
Cellectis S.A. · B-cell Acute Lymphoblastic Leukemia
More on acute lymphoblastic leukemia: recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.